FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options

FDA Commissioner Scott Gottlieb, M.D. is leading the government’s efforts to support the usage of biosimilars. A recent blog posting by the Commissioner focused on the potential cost-saving benefits of the drugs, noting that seven biosimilars have been approved by the FDA’s Center for Drug Evaluation and Research (CDER) to date. Gottlieb writes, “As with the significant savings that we’ve seen through the introduction of generic drugs in the United States, biosimilars could also lead to substantial savings, thereby potentially improving access and promoting better public health outcomes. Understanding the rigorous process FDA uses to evaluate biosimilars can help prescribers and patients maximize the benefits from these products.”
FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options
https://blogs.fda.gov/fdavoice/index.php/2017/10/fda-taking-new-steps-to-better-inform-physicians-about-biosimilars-through-education-about-these-potentially-cost-saving-options/

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.

Name(Required)

Find a UR Rheumatologist Near Me

© 2023 United Rheumatology